Remember the purpose of this company is to sell and market the product (as outlined in the sub-license agreement), as well as develop the app for the product and serve as a fundraising vehicle for Nanobeak, (I think Nanobeak also uses VNTH as a debt shelter when they raise funds).
So, if clinical trials go well on or around Jan 1, 2019 the product will be able to be developed en-masse (the last 10-Q mentions using 3-d printing to rapidly develop the prototypes that will be first used in the industry).
VNTH will need either a private placement or a cash advance from a "related party" (Nanobeak) in order to pay off the short-term convertible debt so that the class C and class D shares become convertible. Once this is done the company can go current start selling products and developing more and more apps and other IP to use the sensor in other areas (opioids, VOC's, etc.).
Once the debt is wiped clean and the company is current and in business the sky is truly the limit here.
News 
Market Data 
Discover 
